XOMA Royalty (NASDAQ:XOMA) Downgraded to Hold Rating by Lucid Cap Mkts

Key Points

• Ligand agreed to acquire XOMA Royalty in an all‑cash deal valuing the company at roughly $739–740M (or $39.00 per share), with a contingent value right (CVR) that leaves additional upside uncertain.
• Lucid Cap Mkts downgraded XOMA from "strong‑buy" to "hold"; analysts are mixed (three Buy, four Hold), giving the stock an overall average rating of "Hold" and an average price target of $68.25.
• Several shareholder law firms have opened investigations alleging the board may not have achieved a fair price—risks that could prompt litigation, regulatory review or a higher bid—while trading activity surged (stock up ~10.7%) and the deal triggered a premarket news halt.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) was downgraded by equities research analysts at Lucid Cap Mkts from a "strong-buy" rating to a "hold" rating in a research note issued to investors on Monday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reissued a "hold (c-)" rating on shares of XOMA Royalty in a research report on Monday, December 29th. Leerink Partners restated an "outperform" rating on shares of XOMA Royalty in a report on Tuesday, February 24th. TD Cowen upgraded XOMA Royalty to a "hold" rating in a research note on Friday, February 13th. Zacks Research raised XOMA Royalty from a "strong sell" rating to a "hold" rating in a research report on Wednesday, April 8th. Finally, HC Wainwright restated a "buy" rating and set a $97.00 target price on shares of XOMA Royalty in a research note on Friday, March 20th. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, XOMA Royalty currently has an average rating of "Hold" and an average price target of $68.25.

XOMA Royalty Stock Up 10.7%

Shares of NASDAQ:XOMA opened at $41.97 on Monday. The company has a market capitalization of $500.28 million, a price-to-earnings ratio of 28.75 and a beta of 0.68. XOMA Royalty has a 12-month low of $22.29 and a 12-month high of $42.81. The business has a 50-day moving average price of $31.11 and a 200 day moving average price of $30.07. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 1.15.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last announced its earnings results on Wednesday, March 18th. The biotechnology company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.16. XOMA Royalty had a net margin of 45.75% and a return on equity of 10.32%. The company had revenue of $13.76 million during the quarter, compared to analyst estimates of $11.13 million. Sell-side analysts expect that XOMA Royalty will post 0.94 EPS for the current year.

Hedge Funds Weigh In On XOMA Royalty

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XOMA. Citadel Advisors LLC acquired a new stake in XOMA Royalty during the 3rd quarter worth $292,000. Wells Fargo & Company MN raised its holdings in shares of XOMA Royalty by 66.0% in the fourth quarter. Wells Fargo & Company MN now owns 10,755 shares of the biotechnology company's stock valued at $286,000 after buying an additional 4,278 shares during the last quarter. Man Group plc acquired a new stake in shares of XOMA Royalty during the third quarter worth about $247,000. Squarepoint Ops LLC acquired a new stake in shares of XOMA Royalty during the fourth quarter worth about $237,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of XOMA Royalty by 266.6% during the third quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company's stock worth $124,000 after buying an additional 2,346 shares during the last quarter. 95.92% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting XOMA Royalty

Here are the key news stories impacting XOMA Royalty this week:

• Positive Sentiment: Ligand agreed to acquire XOMA in an all‑cash transaction valuing the company at roughly $739–740M (reported as $39.00 per share), with Ligand saying the deal expands its royalty portfolio and is immediately accretive to adjusted EPS. GlobeNewswire deal release
• Positive Sentiment: Analysts remain constructive: recent Buy/Outperform coverage and multiple price targets (median ~$63; some targets materially higher) provide buyout validation and suggest upside vs. the $39 cash. Quiver Quant article
• Positive Sentiment: Insider activity and institutional flows support the move: CEO Owen Hughes recently purchased 100,000 shares, and many funds reported increased holdings last quarter—signals of insider/institutional confidence. Quiver Quant insider & institutional data
• Neutral Sentiment: The deal structure includes $39.00 per share plus a contingent value right (CVR), which introduces uncertainty about additional upside beyond the cash component. Rowley Law PR
• Neutral Sentiment: Trading activity surged and the ticker experienced a premarket news halt, reflecting heavy market interest and information flow; this can amplify intraday volatility. MarketWatch premarket report
• Negative Sentiment: Multiple shareholder law firms have launched investigations alleging the board may not have achieved a fair price or may have breached fiduciary duties—these challenges could lead to litigation, regulatory review, delays, or a higher bid demand. Rowley Law PR Halper Sadeh notice Ademi LLP notice

XOMA Royalty Company Profile

XOMA Royalty NASDAQ: XOMA is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company's business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company's investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.